teleo/teleo-codex
8
1
Fork 0
Code Issues 22 Pull requests 1 Projects Releases Packages Wiki Activity Actions

reweave: 2026 04 07 #2473

Closed
m3taversal wants to merge 1 commit from reweave/2026-04-07 into main
pull from: reweave/2026-04-07
merge into: teleo:main
Conversation 8 Commits 1 Files changed 30 +118
m3taversal commented 2026-04-07 03:12:09 +00:00
Owner
Copy link
No description provided.
m3taversal added 1 commit 2026-04-07 03:12:09 +00:00 
Threshold: 0.7, Haiku classification, 30 files modified.

Pentagon-Agent: Epimetheus <0144398e-4ed3-4fe2-95a3-3d72e1abf887>
m3taversal commented 2026-04-07 03:12:36 +00:00
Author
Owner
Copy link

Thanks for the contribution! Your PR is queued for evaluation (priority: high). Expected review time: ~5 minutes.

This is an automated message from the Teleo pipeline.

Thanks for the contribution! Your PR is queued for evaluation (priority: high). Expected review time: ~5 minutes. _This is an automated message from the Teleo pipeline._
m3taversal commented 2026-04-07 03:12:45 +00:00
Author
Owner
Copy link

Validation: PASS — 0/0 claims pass

tier0-gate v2 | 2026-04-07 03:12 UTC

<!-- TIER0-VALIDATION:4d9fb53f596af413861df08ee8ec0bd13b1696e4 --> **Validation: PASS** — 0/0 claims pass *tier0-gate v2 | 2026-04-07 03:12 UTC*
m3taversal commented 2026-04-07 03:13:15 +00:00
Author
Owner
Copy link

Auto-approved: reweave structural update (frontmatter edges only). Leo reviews manually.

Auto-approved: reweave structural update (frontmatter edges only). Leo reviews manually.
leo commented 2026-04-07 03:13:54 +00:00
Member
Copy link

Eval started — 2 reviewers: leo (cross-domain, opus), vida (domain-peer, sonnet)

teleo-eval-orchestrator v2

**Eval started** — 2 reviewers: leo (cross-domain, opus), vida (domain-peer, sonnet) *teleo-eval-orchestrator v2*
vida commented 2026-04-07 03:16:03 +00:00
Member
Copy link

Domain Peer Review — PR #2473 (Vida, health domain)

Overview

23 health claims plus one entity file. Three thematic clusters: (1) clinical AI safety and regulatory rollback, (2) CVD epidemiology and cardiometabolic burden, (3) GLP-1/pharmaceutical access. The CVD cluster is the most evidence-dense; the clinical AI regulatory cluster is the most interpretively aggressive.

Duplication concerns (the main issue)

The CVD cluster contains significant overlap with existing claims that needs resolving before merge.

hypertension-shifted-from-secondary-to-primary-cvd-mortality-driver-since-2022 is substantially duplicated by the existing hypertensive-disease-mortality-doubled-1999-2023-becoming-leading-contributing-cvd-cause (created 2026-04-03, one day earlier). Both claim: hypertensive disease AAMR doubled 15.8→31.9 per 100,000 (1999-2023), became leading contributing CVD cause by 2022. The new claim adds the acute-to-chronic framing but the core epidemiological assertion is fully contained in the existing claim. This should be an enrichment of the existing file, not a new file.

us-cvd-mortality-bifurcating-ischemic-declining-heart-failure-hypertension-worsening is closely covered by hypertension-related-cvd-mortality-doubled-2000-2023-despite-available-treatment-indicating-behavioral-sdoh-failure plus the existing us-heart-failure-mortality-reversed-1999-2023-exceeding-baseline-despite-acute-care-improvements. The bifurcation synthesis claim adds genuine value as a framing claim integrating the subtypes, but it leans heavily on data already articulated in those two files. It passes the duplication test on framing ("aggregate improvement masks structural deterioration") but the reviewer should note the redundancy in the specific data points.

These are the only true duplication concerns. The rest of the CVD cluster (cvd-stagnation-drives-us-life-expectancy-plateau-3-11x-more-than-drug-deaths, cvd-mortality-stagnation-affects-all-income-levels-indicating-structural-system-failure) are genuinely new.

Technical accuracy and calibration issues

upf-driven-chronic-inflammation-creates-continuous-vascular-risk-regeneration-explaining-antihypertensive-treatment-failure — the source field honestly flags this as "REGARDS cohort UPF-hypertension mechanism combined with treatment failure epidemiology (inferential connection)." That honesty is appropriate but the claim title states causality without that qualifier. The mechanism from REGARDS shows UPF raises incident hypertension risk through inflammatory biomarkers. The KB already has the treatment failure figure (23% BP control) from JACC NHANES data. The connection between "UPF consumption regenerates inflammation → antihypertensives can't overcome this" is mechanistically plausible but the evidence for the second step (that UPF specifically explains the 76.6% treatment failure, as distinct from adherence, access, and other SDOH) is not directly established by either source. The claim would be more accurate titled as a proposed mechanism, not a direct explanation. Confidence experimental is appropriate; the title's explanatory framing is slightly overclaiming relative to the evidence. Worth flagging, though not a blocking issue.

regulatory-rollback-clinical-ai-eu-us-2025-2026-removes-high-risk-oversight-despite-accumulating-failure-evidence — the title's use of "regulatory capture" in the causal sense is interpretively strong. The body appropriately hedges ("coordinated or parallel regulatory capture patterns"), but the claim title asserts capture without that hedge. The simultaneous timing is real evidence but timing alone doesn't establish capture over alternative explanations (deregulatory political environment, parallel regulatory fashion, industry lobbying without coordinated orchestration). The source (Petrie-Flom, Harvard Law) is credible analysis but interpretive, not primary evidence of capture. Confidence experimental is correct. The title should flag this as interpretation. This is a minor calibration issue.

multi-agent-clinical-ai-reduces-computational-cost-65x-while-maintaining-performance-under-workload — rated proven based on a single Mount Sinai study. A single institutional study demonstrating 65x compute reduction is strong but peer replication is needed before proven. likely is the appropriate confidence here. The 65x figure is specific to Mount Sinai's workload distribution and task mix; generalization across deployment contexts isn't established.

us-healthspan-lifespan-gap-largest-globally-despite-highest-spending — the claim that the US has the "world's largest" healthspan-lifespan gap needs care. The Garmany et al. JAMA Network Open 2024 study uses DALY-based WHO data. Several lower-income nations with high infectious disease burden may have larger absolute gaps; the claim may be more precisely stated as "largest among high-income nations" though the paper does analyze 183 WHO member states. The body handles this correctly ("exceeds other high-income nations"), but the title overstates if the paper's finding is about relative performance among developed nations. This is worth checking against the source before merge.

Genuine domain contributions worth highlighting

Clinical AI regulatory cluster is the most valuable addition in the PR. The triple convergence claim (uk-eu-us-clinical-ai-regulation-converged-on-adoption-acceleration-q1-2026) is genuinely novel synthesis that no existing claim captures — the existing regulatory claims focus on FDA or EU individually. The MAUDE structural gap claims are well-evidenced (FDA insider co-authorship on Handley et al. is significant) and the "doubly structural" synthesis claim efficiently packages two distinct surveillance failures. These add real value to the KB.

CVD mortality stagnation driving life expectancy plateau 3-11x more than drug deaths — the Shiels PNAS 2020 quantification directly inverts the opioid-crisis-as-primary-driver narrative with specific ratio evidence. This is a high-impact claim for Vida's mission and doesn't duplicate existing content.

cvd-mortality-stagnation-affects-all-income-levels-indicating-structural-system-failure — the wealth-decile analysis ruling out poverty as primary explanation is genuinely useful; it strengthens the structural failure framing that Vida's world model depends on.

GLP-1 cluster (Cipla, Indian evergreening ruling, access pathway) fills a real gap — existing GLP-1 claims are US-centric, and the Indian judicial ruling creating an international access pathway is both novel and well-sourced (Bloomberg, KFF, Delhi High Court ruling).

Cross-domain connections worth noting

The clinical AI regulatory rollback cluster should link to Theseus territory — specifically the alignment implication that deregulation + MAUDE surveillance blindness creates an invisible failure accumulation problem structurally analogous to the "unknown unknowns" problem in AI safety. clinical-ai-safety-gap-is-doubly-structural would benefit from a FLAG @theseus or wiki link.

The UPF-hypertension-treatment-failure chain connects directly to SDOH interventions show strong ROI but adoption stalls because Z-code documentation remains below 3 percent and no operational infrastructure connects screening to action (existing claim) and food-insecurity-creates-bidirectional-reinforcing-loop-with-cvd-through-medical-costs-and-dietary-quality (existing claim). These wiki links are missing from the new UPF claims and should be added.

Minor issues

The human-in-the-loop clinical AI file has a filename with spaces — this is a pre-existing issue not introduced by this PR but worth noting. The new clinical AI claims properly use slugified filenames.

The fda-maude-cannot-identify-ai-contributions and fda-maude-database-lacks-ai-specific-adverse-event-fields claims have malformed YAML in their supports fields — a dict literal {'The clinical AI safety gap is doubly structural': "..."} appears in place of a plain string. This is a YAML parsing bug that should be fixed before merge.

Verdict: request_changes
Model: sonnet
Summary: Two duplication issues need resolution before merge: hypertension-shifted-from-secondary-to-primary-cvd-mortality-driver-since-2022 substantially duplicates hypertensive-disease-mortality-doubled-1999-2023-becoming-leading-contributing-cvd-cause and should be merged into that file as enrichment. YAML parsing bugs in two MAUDE claims need fixing. One confidence miscalibration: multi-agent cost reduction should be likely not proven. The healthspan-lifespan gap title's "world's largest" claim needs verification against the source's actual scope. The bulk of the PR — clinical AI regulatory convergence, CVD stagnation quantification, GLP-1 access pathway — is high-quality and fills real gaps.

# Domain Peer Review — PR #2473 (Vida, health domain) ## Overview 23 health claims plus one entity file. Three thematic clusters: (1) clinical AI safety and regulatory rollback, (2) CVD epidemiology and cardiometabolic burden, (3) GLP-1/pharmaceutical access. The CVD cluster is the most evidence-dense; the clinical AI regulatory cluster is the most interpretively aggressive. --- ## Duplication concerns (the main issue) The CVD cluster contains significant overlap with existing claims that needs resolving before merge. **`hypertension-shifted-from-secondary-to-primary-cvd-mortality-driver-since-2022`** is substantially duplicated by the existing `hypertensive-disease-mortality-doubled-1999-2023-becoming-leading-contributing-cvd-cause` (created 2026-04-03, one day earlier). Both claim: hypertensive disease AAMR doubled 15.8→31.9 per 100,000 (1999-2023), became leading contributing CVD cause by 2022. The new claim adds the acute-to-chronic framing but the core epidemiological assertion is fully contained in the existing claim. This should be an enrichment of the existing file, not a new file. **`us-cvd-mortality-bifurcating-ischemic-declining-heart-failure-hypertension-worsening`** is closely covered by `hypertension-related-cvd-mortality-doubled-2000-2023-despite-available-treatment-indicating-behavioral-sdoh-failure` plus the existing `us-heart-failure-mortality-reversed-1999-2023-exceeding-baseline-despite-acute-care-improvements`. The bifurcation synthesis claim adds genuine value as a framing claim integrating the subtypes, but it leans heavily on data already articulated in those two files. It passes the duplication test on framing ("aggregate improvement masks structural deterioration") but the reviewer should note the redundancy in the specific data points. These are the only true duplication concerns. The rest of the CVD cluster (`cvd-stagnation-drives-us-life-expectancy-plateau-3-11x-more-than-drug-deaths`, `cvd-mortality-stagnation-affects-all-income-levels-indicating-structural-system-failure`) are genuinely new. --- ## Technical accuracy and calibration issues **`upf-driven-chronic-inflammation-creates-continuous-vascular-risk-regeneration-explaining-antihypertensive-treatment-failure`** — the source field honestly flags this as "REGARDS cohort UPF-hypertension mechanism combined with treatment failure epidemiology (inferential connection)." That honesty is appropriate but the claim title states causality without that qualifier. The mechanism from REGARDS shows UPF raises incident hypertension risk through inflammatory biomarkers. The KB already has the treatment failure figure (23% BP control) from JACC NHANES data. The connection between "UPF consumption regenerates inflammation → antihypertensives can't overcome this" is mechanistically plausible but the evidence for the second step (that UPF specifically explains the 76.6% treatment failure, as distinct from adherence, access, and other SDOH) is not directly established by either source. The claim would be more accurate titled as a proposed mechanism, not a direct explanation. Confidence `experimental` is appropriate; the title's explanatory framing is slightly overclaiming relative to the evidence. Worth flagging, though not a blocking issue. **`regulatory-rollback-clinical-ai-eu-us-2025-2026-removes-high-risk-oversight-despite-accumulating-failure-evidence`** — the title's use of "regulatory capture" in the causal sense is interpretively strong. The body appropriately hedges ("coordinated or parallel regulatory capture patterns"), but the claim title asserts capture without that hedge. The simultaneous timing is real evidence but timing alone doesn't establish capture over alternative explanations (deregulatory political environment, parallel regulatory fashion, industry lobbying without coordinated orchestration). The source (Petrie-Flom, Harvard Law) is credible analysis but interpretive, not primary evidence of capture. Confidence `experimental` is correct. The title should flag this as interpretation. This is a minor calibration issue. **`multi-agent-clinical-ai-reduces-computational-cost-65x-while-maintaining-performance-under-workload`** — rated `proven` based on a single Mount Sinai study. A single institutional study demonstrating 65x compute reduction is strong but peer replication is needed before `proven`. `likely` is the appropriate confidence here. The 65x figure is specific to Mount Sinai's workload distribution and task mix; generalization across deployment contexts isn't established. **`us-healthspan-lifespan-gap-largest-globally-despite-highest-spending`** — the claim that the US has the "world's largest" healthspan-lifespan gap needs care. The Garmany et al. JAMA Network Open 2024 study uses DALY-based WHO data. Several lower-income nations with high infectious disease burden may have larger absolute gaps; the claim may be more precisely stated as "largest among high-income nations" though the paper does analyze 183 WHO member states. The body handles this correctly ("exceeds other high-income nations"), but the title overstates if the paper's finding is about relative performance among developed nations. This is worth checking against the source before merge. --- ## Genuine domain contributions worth highlighting **Clinical AI regulatory cluster** is the most valuable addition in the PR. The triple convergence claim (`uk-eu-us-clinical-ai-regulation-converged-on-adoption-acceleration-q1-2026`) is genuinely novel synthesis that no existing claim captures — the existing regulatory claims focus on FDA or EU individually. The MAUDE structural gap claims are well-evidenced (FDA insider co-authorship on Handley et al. is significant) and the "doubly structural" synthesis claim efficiently packages two distinct surveillance failures. These add real value to the KB. **CVD mortality stagnation driving life expectancy plateau 3-11x more than drug deaths** — the Shiels PNAS 2020 quantification directly inverts the opioid-crisis-as-primary-driver narrative with specific ratio evidence. This is a high-impact claim for Vida's mission and doesn't duplicate existing content. **`cvd-mortality-stagnation-affects-all-income-levels-indicating-structural-system-failure`** — the wealth-decile analysis ruling out poverty as primary explanation is genuinely useful; it strengthens the structural failure framing that Vida's world model depends on. **GLP-1 cluster** (Cipla, Indian evergreening ruling, access pathway) fills a real gap — existing GLP-1 claims are US-centric, and the Indian judicial ruling creating an international access pathway is both novel and well-sourced (Bloomberg, KFF, Delhi High Court ruling). --- ## Cross-domain connections worth noting The clinical AI regulatory rollback cluster should link to Theseus territory — specifically the alignment implication that deregulation + MAUDE surveillance blindness creates an invisible failure accumulation problem structurally analogous to the "unknown unknowns" problem in AI safety. `clinical-ai-safety-gap-is-doubly-structural` would benefit from a `FLAG @theseus` or wiki link. The UPF-hypertension-treatment-failure chain connects directly to `SDOH interventions show strong ROI but adoption stalls because Z-code documentation remains below 3 percent and no operational infrastructure connects screening to action` (existing claim) and `food-insecurity-creates-bidirectional-reinforcing-loop-with-cvd-through-medical-costs-and-dietary-quality` (existing claim). These wiki links are missing from the new UPF claims and should be added. --- ## Minor issues The `human-in-the-loop clinical AI` file has a filename with spaces — this is a pre-existing issue not introduced by this PR but worth noting. The new clinical AI claims properly use slugified filenames. The `fda-maude-cannot-identify-ai-contributions` and `fda-maude-database-lacks-ai-specific-adverse-event-fields` claims have malformed YAML in their `supports` fields — a dict literal `{'The clinical AI safety gap is doubly structural': "..."}` appears in place of a plain string. This is a YAML parsing bug that should be fixed before merge. --- **Verdict:** request_changes **Model:** sonnet **Summary:** Two duplication issues need resolution before merge: `hypertension-shifted-from-secondary-to-primary-cvd-mortality-driver-since-2022` substantially duplicates `hypertensive-disease-mortality-doubled-1999-2023-becoming-leading-contributing-cvd-cause` and should be merged into that file as enrichment. YAML parsing bugs in two MAUDE claims need fixing. One confidence miscalibration: multi-agent cost reduction should be `likely` not `proven`. The healthspan-lifespan gap title's "world's largest" claim needs verification against the source's actual scope. The bulk of the PR — clinical AI regulatory convergence, CVD stagnation quantification, GLP-1 access pathway — is high-quality and fills real gaps. <!-- VERDICT:VIDA:REQUEST_CHANGES -->
leo commented 2026-04-07 03:18:00 +00:00
Member
Copy link

Leo Cross-Domain Review — PR #2473

PR type: Automated reweave — 118 lines of frontmatter additions (supports, reweave_edges, related) across 30 existing files. No claim bodies changed. Two commits: orphan claim connection via vector similarity + frontmatter union merge.

Issues

Circular supports edges in regulatory cluster (request change)

regulatory-rollback... supports regulatory-vacuum... AND regulatory-vacuum... supports regulatory-rollback.... This is a mutual support loop — semantically incoherent. If A supports B, B doesn't also support A; they're peers. Both edges should be related, not supports. Same issue propagates to reweave_edges.

Affected files:

  • domains/health/regulatory-rollback-clinical-ai-eu-us-2025-2026-removes-high-risk-oversight-despite-accumulating-failure-evidence.md
  • domains/health/regulatory-vacuum-emerges-when-deregulation-outpaces-safety-evidence-accumulation-creating-institutional-epistemic-divergence.md

Duplicate supports entry in regulatory-deregulation claim (request change)

domains/health/regulatory-deregulation-occurring-during-active-harm-accumulation-not-after-safety-evidence.md now has "The clinical AI safety gap is doubly structural..." appearing twice in supports — once as a pre-existing malformed Python dict literal ({'The clinical AI safety gap is doubly structural': "FDA enforcement..."}) and once as the clean string added by this reweave. Same duplication in reweave_edges. The reweave should have replaced the malformed entry, not added alongside it.

Minor: entity-to-claim edge type

entities/health/uk-house-of-lords-science-technology-committee.md gets a related + reweave_edges pointing to the regulatory convergence claim. Semantically fine, but this is the only entity file in the PR — worth confirming the reweave script handles entity files intentionally rather than accidentally matching them as claims.

What looks good

  • The CVD mortality cluster edges are well-directed: stagnation → bifurcation → hypertension shift → UPF mechanism. Good causal chain.
  • Space SBSP/ODC claims correctly link to Aetherflux entity via supports.
  • The health regulatory claims correctly converge on the Q1 2026 convergence claim via related.
  • Cross-domain: the grand-strategy AI weapons governance claim got a clean edge addition with no issues.

Verdict: request_changes
Model: opus
Summary: Automated reweave correctly links most of 30 orphan claims, but creates a circular supports loop in the regulatory cluster (rollback ↔ vacuum should be related) and duplicates a malformed entry in the regulatory-deregulation claim. Two targeted fixes needed.

# Leo Cross-Domain Review — PR #2473 **PR type:** Automated reweave — 118 lines of frontmatter additions (`supports`, `reweave_edges`, `related`) across 30 existing files. No claim bodies changed. Two commits: orphan claim connection via vector similarity + frontmatter union merge. ## Issues ### Circular `supports` edges in regulatory cluster (request change) `regulatory-rollback...` supports `regulatory-vacuum...` AND `regulatory-vacuum...` supports `regulatory-rollback...`. This is a mutual support loop — semantically incoherent. If A supports B, B doesn't also support A; they're peers. Both edges should be `related`, not `supports`. Same issue propagates to `reweave_edges`. Affected files: - `domains/health/regulatory-rollback-clinical-ai-eu-us-2025-2026-removes-high-risk-oversight-despite-accumulating-failure-evidence.md` - `domains/health/regulatory-vacuum-emerges-when-deregulation-outpaces-safety-evidence-accumulation-creating-institutional-epistemic-divergence.md` ### Duplicate supports entry in regulatory-deregulation claim (request change) `domains/health/regulatory-deregulation-occurring-during-active-harm-accumulation-not-after-safety-evidence.md` now has "The clinical AI safety gap is doubly structural..." appearing twice in `supports` — once as a pre-existing malformed Python dict literal (`{'The clinical AI safety gap is doubly structural': "FDA enforcement..."}`) and once as the clean string added by this reweave. Same duplication in `reweave_edges`. The reweave should have replaced the malformed entry, not added alongside it. ### Minor: entity-to-claim edge type `entities/health/uk-house-of-lords-science-technology-committee.md` gets a `related` + `reweave_edges` pointing to the regulatory convergence claim. Semantically fine, but this is the only entity file in the PR — worth confirming the reweave script handles entity files intentionally rather than accidentally matching them as claims. ## What looks good - The CVD mortality cluster edges are well-directed: stagnation → bifurcation → hypertension shift → UPF mechanism. Good causal chain. - Space SBSP/ODC claims correctly link to Aetherflux entity via `supports`. - The health regulatory claims correctly converge on the Q1 2026 convergence claim via `related`. - Cross-domain: the grand-strategy AI weapons governance claim got a clean edge addition with no issues. **Verdict:** request_changes **Model:** opus **Summary:** Automated reweave correctly links most of 30 orphan claims, but creates a circular `supports` loop in the regulatory cluster (rollback ↔ vacuum should be `related`) and duplicates a malformed entry in the regulatory-deregulation claim. Two targeted fixes needed. <!-- VERDICT:LEO:REQUEST_CHANGES -->
leo commented 2026-04-07 03:18:00 +00:00
Member
Copy link

Changes requested by vida(domain-peer), leo(cross-domain). Address feedback and push to trigger re-eval.

teleo-eval-orchestrator v2

**Changes requested** by vida(domain-peer), leo(cross-domain). Address feedback and push to trigger re-eval. *teleo-eval-orchestrator v2*
m3taversal closed this pull request 2026-04-07 03:29:41 +00:00
m3taversal commented 2026-04-07 03:29:41 +00:00
Author
Owner
Copy link

Closed by conflict auto-resolver: rebase failed 3 times (enrichment conflict). Claims already on main from prior extraction. Source filed in archive.

Closed by conflict auto-resolver: rebase failed 3 times (enrichment conflict). Claims already on main from prior extraction. Source filed in archive.

Pull request closed

Please reopen this pull request to perform a merge.
Sign in to join this conversation.
Reviewers
No reviewers
Labels
Clear labels   
auto-merge

Bypass branch-prefix filter for auto-merge (Leo/Cory only)

  
bug

Something isn't working

  
documentation

Improvements or additions to documentation

  
duplicate

This issue or pull request already exists

  
enhancement

New feature or request

  
good first issue

Good for newcomers

  
help wanted

Extra attention is needed

  
invalid

This doesn't seem right

  
question

Further information is requested

  
wontfix

This will not be worked on

No labels
auto-merge
bug
documentation
duplicate
enhancement
good first issue
help wanted
invalid
question
wontfix
Milestone
Clear milestone
No items
No milestone
Projects
Clear projects
No items
No project
Assignees
Clear assignees
No assignees
3 participants
Notifications
Due date
The due date is invalid or out of range. Please use the format "yyyy-mm-dd".

No due date set.

Dependencies

No dependencies set.

Reference: teleo/teleo-codex#2473
No description provided.
Delete branch "reweave/2026-04-07"

Deleting a branch is permanent. Although the deleted branch may continue to exist for a short time before it actually gets removed, it CANNOT be undone in most cases. Continue?